DNB Asset Management AS raised its holdings in Pfizer Inc. (NYSE:PFE – Free Report) by 38.5% in the fourth quarter, Holdings Channel reports. The firm owned 1,753,086 shares of the biopharmaceutical company’s stock after purchasing an additional 486,895 shares during the period. DNB Asset Management AS’s holdings in Pfizer were worth $43,652,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors have also recently bought and sold shares of the company. Horizon Financial Services LLC grew its stake in Pfizer by 174.8% in the 4th quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 645 shares during the period. YANKCOM Partnership bought a new position in shares of Pfizer during the 4th quarter worth $28,000. HFM Investment Advisors LLC grew its stake in shares of Pfizer by 61.0% during the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 427 shares during the period. Grey Fox Wealth Advisors LLC purchased a new stake in Pfizer in the 3rd quarter worth about $29,000. Finally, Darwin Wealth Management LLC bought a new stake in Pfizer in the 2nd quarter valued at about $32,000. Institutional investors own 68.36% of the company’s stock.
Pfizer Price Performance
Shares of Pfizer stock opened at $25.31 on Friday. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67. The firm has a market capitalization of $144.25 billion, a PE ratio of 19.32 and a beta of 0.35. The business’s 50-day moving average price is $26.98 and its 200-day moving average price is $26.19. Pfizer Inc. has a 12 month low of $22.45 and a 12 month high of $28.75.
Pfizer Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 12th. Stockholders of record on Friday, May 8th will be given a dividend of $0.43 per share. The ex-dividend date is Friday, May 8th. This represents a $1.72 annualized dividend and a dividend yield of 6.8%. Pfizer’s dividend payout ratio is 131.30%.
Analyst Ratings Changes
A number of equities research analysts recently issued reports on PFE shares. Weiss Ratings upgraded Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, May 6th. Citigroup boosted their price objective on Pfizer from $26.00 to $27.00 and gave the company a “neutral” rating in a research note on Wednesday, April 29th. BMO Capital Markets restated an “outperform” rating and issued a $30.00 price objective on shares of Pfizer in a research note on Monday, March 9th. CICC Research initiated coverage on Pfizer in a research note on Thursday, April 16th. They issued an “outperform” rating and a $33.00 price objective on the stock. Finally, Bank of America dropped their price objective on Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a report on Thursday, April 9th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, twelve have given a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $28.84.
Check Out Our Latest Stock Report on PFE
Key Headlines Impacting Pfizer
Here are the key news stories impacting Pfizer this week:
- Positive Sentiment: Pfizer announced a Europe label expansion for its hemophilia therapy Hympavzi, which could broaden the drug’s commercial opportunity and support long-term revenue growth.
- Positive Sentiment: Multiple updates highlighted ongoing clinical and development activity, including a new Korea migraine study for Nurtec ODT, a Phase 1 food-effect study for PF-07799933, a prazosin site-transfer trial, and a planned Japan RSV vaccine trial. These reinforce Pfizer’s pipeline and global expansion efforts.
- Positive Sentiment: Recent commentary around Pfizer’s Q1 earnings pointed to improving momentum in new and acquired products, especially oncology and migraine treatments, as well as progress from the Seagen integration and legal settlements that may improve clarity around future cash flow.
- Neutral Sentiment: Media coverage also noted that investor sentiment remains mixed, with some analysts and commentators arguing Pfizer still lacks strong earnings momentum and is being supported more by its dividend and defensive valuation than by a clear near-term growth catalyst.
- Negative Sentiment: Pfizer continues to face concerns about declining COVID-related sales and looming patent expirations, which have weighed on the stock even after earnings beat expectations.
About Pfizer
Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.
Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.
Read More
- Five stocks we like better than Pfizer
- Viking Sails to All-Time Highs—Fundamentals Signal More to Come
- Datavalut Gains Traction: 5 Reasons to Sell Now
- TMC Stock: Why This Pre-Revenue Miner Is Worth Watching
- The Power Grid Is Dying—Is It Time to Buy Its Replacement?
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.
